Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426425 | 0.85 | PIM1 (0.41) | SLC40A1KAT6APTGES2ALDH1A1HSD17B10 | |
| SCHEMBL8075337 | 0.82 | CA2 (0.55) | SLC40A1KAT6APTGES2 | |
| SCHEMBL22545576 | 0.82 | KAT6A (0.51) | SLC40A1KAT6APTGES2SLC22A12HDAC3 | |
| SCHEMBL862985 | 0.82 | ABL1 (0.49) | SLC40A1KAT6APTGES2SLC22A12HDAC3 | |
| SCHEMBL4190483 | 0.81 | FFAR4 (0.38) | SLC40A1KAT6APTGES2SLC22A12FBP1 | |
| Hydrochloric Acid SCHEMBL27913690 | 0.81 | KAT6A (0.50) | SLC40A1KAT6APTGES2SLC22A12HDAC3 | |
| SCHEMBL22954096 | 0.81 | KAT6A (0.53) | SLC40A1KAT6APTGES2SLC22A12NAMPT | |
| SCHEMBL14572884 | 0.79 | KDM2B (0.48) | SLC40A1KAT6APTGES2HDAC3HDAC4 | |
| SCHEMBL9778961 | 0.79 | PTGES2 (0.52) | SLC40A1KAT6APTGES2SLC22A12HDAC3 | |
| SCHEMBL27383227 | 0.79 | SLC22A12 (0.43) | SLC40A1KAT6APTGES2SLC22A12CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320374-B | Method for synthesizing 3-sulfonyl substituted chromone derivative by photocatalysis | JIANG University OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| EP-4596534-A1 | NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION | University of Copenhagen (DK) | 2025-08-06 | — | — | EP | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119462588-A | Flavone derivative containing sulfonamide structure and preparation method and application thereof | 上海中医药大学附属曙光医院 | 2025-02-18 | — | — | CN | disclosed |
| CN-119320374-A | Method for synthesizing 3-sulfonyl substituted chromone derivative by photocatalysis | 浙江工业大学 | 2025-01-17 | — | — | CN | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | SLC40A1 2458/4885KAT6A 432/4885PTGES2 2076/4885 |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | SLC40A1 4501/4885KAT6A 1846/4885PTGES2 2520/4885 |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | SLC40A1 719/4885KAT6A 3450/4885PTGES2 4803/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | SLC40A1 3214/4885KAT6A 4521/4885PTGES2 516/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | SLC40A1 1814/4885KAT6A 727/4885PTGES2 2731/4885 |
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | SLC40A1 323/4885KAT6A 827/4885PTGES2 2870/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | SLC40A1 2772/4885KAT6A 862/4885PTGES2 1302/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | SLC40A1 3649/4885KAT6A 1291/4885PTGES2 35/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | SLC40A1 4580/4885KAT6A 1346/4885PTGES2 27/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | SLC40A1 3579/4885KAT6A 2910/4885PTGES2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.